Atorvastatin + Evolocumab
Phase 3CompletedDevelopment Stage
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Oct 1, 2013 → Jun 1, 2014
About Atorvastatin + Evolocumab
Atorvastatin + Evolocumab is a phase 3 stage product being developed by Amgen for Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events. The current trial status is completed. This product is registered under clinical trial identifier NCT01953328. Target conditions include Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events.
What happened to similar drugs?
8 of 20 similar drugs in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01953328 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events